Page 10 - Vaccine

Govt launches U-WIN to digitise India's universal immunisation programme

Carrying vaccination cards of children and pregnant women, struggling to keep a tab on the next jab and other such hassles may soon become a thing of the past. After the success of the Co-WIN platform, the government has now replicated it to set up an electronic registry for routine vaccinations. Named U-WIN, the programme to digitise India's Universal Immunisation Programme (UIP) has been launched in a pilot mode in two districts of each state and Union Territory. The platform will be used to register and vaccinate every pregnant woman, record her delivery outcome, register every newborn delivery, administer birth doses and all vaccination events thereafter, official sources told PTI. The platform that replicates Co-WIN, which has served as the "digital backbone" for India's COVID-19 vaccination programme, was launched on January 11 in 65 districts. The U-WIN is going to be the single source of information for immunisation services, updating vaccination status, delivery outcome, .

SII seeks inclusion of Covovax in CoWIN portal as booster dose for adults

Covovax is manufactured through technology transfer from Novavax

India in advanced stage to deliver on global plan for TB vaccine: Mandaviya

Health Minister Mansukh Mandaviya extended his full support for a global plan for a new tuberculosis vaccine by 2025 and said India is fully prepared and in an advanced stage for taking this forward

Govt exempts customs duty on imports of Covid-19 vaccines till March 31

Currently, Covid vaccines administered in India include Covishield, Covaxin, Sputnik V, Corbevax and Covovax

Acceptance of Covid vaccines increased globally to 79.1% in 2022: Study

Acceptance of COVID-19 vaccines increased globally, from 75.2 per cent in 2021 to 79.1 per cent in 2022, according to a survey in 23 countries that represent more than 60 per cent of the world's population. The study underlines a wide variability among countries and the need for tailored communication strategies in addressing vaccine hesitancy. It was led by the Barcelona Institute for Global Health (ISGlobal), Spain, and the City University of New York Graduate School of Public Health and Health Policy (CUNY SPH), US. However, vaccine acceptance decreased in eight countries and almost one in eight vaccinated respondents, particularly younger men and women, were hesitant about receiving a booster dose, the study said. The findings have been published in Nature Medicine. "The pandemic is not over, and authorities must urgently address vaccine hesitancy and resistance as part of their COVID-19 prevention and mitigation strategy," says Jeffrey V Lazarus, Head of the Health Systems ...

Govt panel may decide on Covovax as heterologous booster dose for adults

An expert panel of the central drugs regulatory authority is likely to take a decision on Wednesday on granting market authorisation to SII's COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin, official sources said. The Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO) is scheduled to meet on January 11. Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII), had written a letter to the the Drugs Controller General of India (DCGI) recently for the approval to Covovax as a heterologous booster dose for adults in view of the escalating pandemic situation in some countries, an official source told. The DCGI had approved Covovax for restricted use in emergency situations for adults on December 28, 2021, for those in the 12-17 age group on March 9, 2022, and also in children aged 7- 11 years on June 28, 2022, subject to certai

Clinical trials of new BCG vaccine for TB to start soon: Former CSIR chief

Clinical trials of a new BCG vaccine for tuberculosis will soon start in India, former director-general of the Council of Scientific & Industrial Research (CSIR) Dr Shekhar Mande said on Friday. He was speaking at the ongoing Indian Science Congress here. Earlier in the day, Dr Mande gave a presentation on Biophysical Methods in Tuberculosis Research' and spoke about how technology has helped doctors and researchers understand TB better, paving ways to combat the infectious disease. The CSIR is working towards rapid diagnosis, vaccination and treatment to eliminate the bacterial disease from India by 2025 as envisioned by the government, he said, speaking to reporters later. We are mainly focussing on new medicines and drugs for tuberculosis. We are doing background work and setting targets on research for prevention of tuberculosis, he said The National Institute of Tuberculosis Research, Chennai, will start clinical trials of the new BCG vaccine for TB, he said. Bacillus ...

All you need to know about world's first nasal vaccine for covid

The government has approved Bharat Biotech's intranasal Covid-19 vaccine, iNCOVACC (BBV154), as a booster dose for those above 18 years of age. How does this needle-free vaccine work and how different is it from the existing ones? To get the answers, Business Standard spoke to Dr Gagandeep Kang, virologist and professor at the Christian Medical College, Vellore. Watch the video for more

India's nasal vaccine not for those who have taken booster: NTAGI chairman

The Indian nasal vaccine cannot be given to those who have allready taken a precaution or booster dose, the head of the country's vaccine task force said

We aim to be one of India's top CDMO, API players: Advent's Shweta Jalan

'Suven alone has multiple engines of growth across all segments and a strong pipeline of Phase 3 and late Phase 2 molecules'

Covid-19: Bharat Biotech's nasal vaccine gets govt nod as booster shot

The approval for the vaccine comes amid a spurt in Covid cases in China and some other countries

As Covid-19 cases fall, Indians drag feet to get their booster shots

Less than 30,000 booster doses daily in December, vaccine coverage flat for two months

DCGI approves Biological E's 14-valent pneumococcal conjugate vaccine

PCV14 may be administered to infants 6, 10 and 14 weeks of age in 3 doses

Takeda's dengue vaccine QDENGA gets EU's authorisation use approval

The vaccine, branded QDENGA, is designed for use those aged 4 and older to prevent any of the four so-called serotypes of dengue.

Meta bars employees from discussing abortion, vaccine efficacy at work

Meta (formerly Facebook) has reportedly told its employees not to discuss sensitive issues like abortion, gun control, pending legislation and vaccine efficacy at workplace

Lessons from Covid: Pharma firms turn attention to adult vaccination

Vaccine companies have warmed up to the idea of adult vaccines for other diseases such as pneumonia, flu and shingles as well

4.8 mn children to get Japanese Encephalitis vaccine from Dec 5: K'taka Min

A special vaccination drive to inoculate an estimated 48 lakh children aged between 1-15 against Japanese Encephalitis (JE) will be held in Karnataka from December 5 for a period of three weeks, State Health Minister K Sudhakar said on Sunday. Encephalitis is the inflammation of the brain caused by either infection or an allergic reaction. "JE is one of the most common causes of Encephalitis in India and a total of 68,000 cases are reported every year. Among these, the death rate is around 20 to 30 per cent. Among those who are cured, 30 to 50 per cent of people end up with sensory and motor weakness, and other permanent physical and mental disabilities," Sudhakar said. "In the first week now (December), vaccinations will primarily be focused on Private and Government schools, following this, in the next two weeks, we will be focusing on vaccination drives in health institutions, Anganwadi centers and among communities," he said. Union Health Ministry will be supplying the Jenvac .

With the flu season here, should you ask for an influenza vaccine?

Demand for flu vaccine weak in India; US facing worst season in a decade

Bharat Bio looks for partners to manufacture, distribute iNCOVACC globally

Its local production ramp-up remains unhurried as demand for boosters reduces

Bharat Biotech gets nasal vaccine nod for use as mix-match booster

iNCOVACC first intranasal Covid shot to receive approval for primary 2-dose schedule, heterologous booster us